Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

All: Brain, nervous system

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

The purpose of this study is to compare what effects, good and/or bad, a vaccine called HSPPC-96 given with a drug called bevacizumab versus bevacizumab alone has on recurrent glioblastoma multiforme (GBM).

Status: Accepting New Patients
Principal Investigator: Orin Bloch

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

A Phase II, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent malignant glioma with Tremelimumab and Durvalumab (MEDI4736) alone and in combination to determine immunologic changes from treatment.

The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient’s immune system attack their tumor (Glioblastoma Multiforme – GBM). These drugs have already shown benefit in some other cancer types and are now being explored in GBM.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma

The purpose of this research study is to determine the effects (good and bad) bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with Or without Hippocampal Avoidance In Patients with Brain Metastases

To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation can decrease the risk of cognitive side effects after radiation therapy to the brain to using the usual whole-brain radiation plus memantine (a drug that can also reduce cognitive side effects of brain radiation).

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas

The purpose of this study is to determine the effectiveness and safety of combining multiple types of treatments for patients who have recurrent high grade brain tumors.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma

The purpose of this study is to compare a different radiation therapy schedule and higher radiation dose [higher dose group] to the standard dose of radiation therapy [standard dose group].

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Sun - February 19, 2017 - 08:15 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.